Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma

• Main Authors: Xiaoyue Zeng (Author), Lu Xue (Author), Wei Li (Author), Ping Zhao (Author), Weiwei Chen (Author), Wenyi Wang (Author), Jinhua Shen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Vandetanib is a small-molecule tyrosine kinase inhibitor. It exerts its therapeutic effects primarily in a range of lung cancers by inhibiting the vascular endothelial growth factor receptor 2. However, it remains unclear whether vandetanib has therapeutic benefits in other lung diseases...